Genprex Inc. Regains Nasdaq $1.00 Bid Price Compliance

What Happened

• Genprex, Inc. (GNPX) announced that the Nasdaq Hearings Panel notified the company on July 29, 2026 that it granted Genprex’s request to continue listing and to be excepted from the $1.00 minimum bid price requirement. On August 4, 2026 the Panel formally notified Genprex that it has regained compliance with Nasdaq Listing Rule 5550(a)(2).
• The Panel said Genprex must maintain a closing bid price of at least $1.00 each trading day through December 7, 2026 (the full extent of the Panel’s discretion) and that the Panel will retain jurisdiction over the company until that date.

Key Details

• Date of initial Panel action: July 29, 2026; formal determination of compliance: August 4, 2026.
• Requirement: closing bid ≥ $1.00 for every trading day through December 7, 2026.
• If Genprex becomes non‑compliant with any other Nasdaq listing rule before Dec 7, 2026, it will have 7 calendar days to present a plan to the Panel, which will then decide whether to grant an exception or delist.

Why It Matters

• This filing confirms Genprex avoided immediate delisting over the minimum bid price and remains listed on The Nasdaq Capital Market for now, preserving trading liquidity and investor access.
• The company remains under Panel oversight until December 7, 2026 and must meet the daily $1.00 bid requirement; failure to meet other listing rules could prompt a quick review and potential delisting action.